The global active pharmaceutical ingredient market
is expected to reach approximately $175 billion by 2020, growing at a CAGR of
around 6% during forecast period. Active pharmaceutical ingredient is any
substance or mixture of substances used in a finished pharmaceutical product
with pharmacological activity used for diagnosis, cure, mitigation, treatment
and prevention of diseases. Very less number of finished pharmaceutical product
manufacturers has their own API manufacturing unit and nobody can make all
required APIs in-house. It is basically not easy for API manufacturers in
developing countries to ensure a product with quality at a reasonable price.
API manufacturing involves conversion of raw materials into API and mixing API
and excipients for final formulations. These formulations in the form of
tablets, capsules or solutions are packaged and then marketed.
Patent expiration of major drugs that increased
generic drug sales, government initiatives, increasing aged population and
regional penetration, local manufacturer expansion and high uptake of biologics
are some of the factors that are driving the market growth. Whereas financial
crisis, stringent regulatory policies, less investment in pharmaceutical
industry and fragmented market are the factors that are hindering API market
growth.
The global API market is segmented based on
synthesis, customer base, business type and therapeutic applications. Depending
on synthesis the market is classified into synthetic chemical API, biotech API
and HPAPI (Highly Potent Active Pharmaceutical Ingredient). Biotech API is
further segmented into mammalian cell culture, monoclonal antibodies,
recombinant proteins, vaccines, insulin analog, growth hormones and
interferons. Mammalian cell culture accounted for the largest share in 2013,
while monoclonal antibody segment is the fastest growing segment by 2020.
Despite low production yields, high manufacturing cost and highly unstable cell
culturing method mammalian culture is the largest due to post-translational
mechanism present in living cells. Monoclonal antibodies are growing at a
faster pace due to demand for biotech APIs and increasing venture capital
investments that drives the market.
By-customer base the API market is segmented into
synthetic chemicals API, biotech API and HPAPI. Synthetic chemical API is
further classified into branded/innovative and generic/non-branded API. Branded
API accounted for the largest share whereas, generic is the fastest growing
segment. Biotech API is further divided into biologics and biosimilars where
biologics accounted for the largest share.
Depending on business type the API market is
segmented into captive and merchant. Captive market accounted for the largest
revenue in 2013. Based on the
therapeutic applications the global API market is categorized into eleven
crucial application areas such as anti-infectives, oncology, cardiovascular and
hematopoietic system, central nervous system, gastrointestinal disorder,
respiratory system, hormonal-related disorder, metabolic disorder,
genito-urinary disorder, musculo-skeletal disorder and others. Anti-infectives
segment dominated the application market with a largest in 2013 whereas
oncology segment is the fastest growing segment with a CAGR of approximately 8%
by 2020. Patent expiration of major drugs, increased incidence of various
cancer diseases and aged population, high government investments for cancer
research and healthcare awareness are the factors that drives the market
whereas stringent regulations, failure of crucial drugs in last stage of
clinical trial, and economical crisis are the factors that hampers the market
growth.
Geographically API market is segmented into North
America, Asia-Pacific, Europe and Rest of the world regions. North America
dominated the global API market during the forecast period. Asia Pacific region
is the fastest growing with a CAGR of more than 7.5% by 2020 due to patent
expirations of drugs, low operation costs, services of Contract Manufacturing
Organizations (CMO) and high investments in medical research. Moreover the high
cost of skilled labor and energy are the major factors that forced European
market to shift their base to countries such as India and China.
Major players in the API market include Teva Active
Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr.
Reddy's Lab (India), Boehringer Ingelheim GmbH (Germany), Lonza group
(Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India),
and Albemarle Corporation (U.S.).
Spanning over 282 pages and 51 Tables “Active
Pharmaceutical Ingredients Global Market – Forecast to 2020” report covers Executive
Summary, Introduction, Market Analysis, Global Api Market Overview, Global Api Market, By Therapeutic Application, Regional Market Analysis,
Company Developments, Major Player Profiles. This Report Covered 11 Companies -
Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories
(India), Dr. Reddy's Lab (India), Boehringer Ingelheim Gmbh (Germany), Lonza
Group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo Pharma
(India), Albemarle Corporation (U.S.), Sun Pharmaceuticals (India), Fresenius
Kabi (Germany).
For
further information on this report, please visit- http://mrr.cm/4fP
Find all Pharmaceutical Manufacturing Reports at: http://www.marketresearchreports.com/pharmaceutical-manufacturing
No comments:
Post a Comment
Note: only a member of this blog may post a comment.